

Desmoid Tumour Treatment Outcome: A Single Institution Experience

Mohamed Wahba Hegazy^{1,2,*}, Mohamed Rizwanullah¹

¹Section of Radiation Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

²Department of Clinical Oncology and Nuclear Medicine, Zagazig College of Medicine, Zagazig, Egypt

Email address:

F1501625@gmail.com (Mohamed Wahba Hegazy)

*Corresponding author

To cite this article:

Mohamed Wahba Hegazy, Mohamed Rizwanullah. Desmoid Tumour Treatment Outcome: A Single Institution Experience. *Journal of Cancer Treatment and Research*. Vol. 10, No. 4, 2022, pp. 38-42. doi: 10.11648/j.jctr.20221004.11

Received: November 3, 2022; **Accepted:** November 21, 2022; **Published:** December 27, 2022

Abstract: Desmoid tumors are benign tumor of connective tissue but with high chances of local recurrence. Surgery is the main treatment modality of therapy if it can be done with acceptable morbidity. Our purpose to present our experience in management of desmoid tumors and our aim is to evaluate the best option in dealing with desmoid tumors and factors affecting the Recurrence Free Survival. This is retrospective trial so medical records of patients diagnosed as desmoid tumors between January 2009 and December 2018 were reviewed at Radiation Oncology section, King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, Saudi Arabia. Our cohort was 72 consecutive patients. The median age was 27 years, two-thirds were females, median size was 7 cm and most common site was trunk. Twenty four patients were treated with definitive radiotherapy, 15 patients by surgical resection alone and 30 patients by combination of both surgery and radiotherapy. The median follow up was 5.5 years with local control in patients who had radiotherapy as part of treatment was 89% and 87% in patients who had surgery as a part of treatment. The patients who had surgery alone had no recurrence. All the recurrences happened in the lower radiotherapy dose of 50Gy and those who had postoperative radiotherapy. There was no recurrence in the higher radiotherapy dose of 60Gy and those who had preoperative radiotherapy. Most of the recurrence was in patients with tumor size less than 5 cm, in the extremities and in the less than 30 years old group. The 3 years, 5 years and 7years Recurrence Free Survival in patients who had both surgery and radiotherapy was 96.4%, 81.4% and 77.4% respectively. Radiotherapy plays an important role in local control of desmoid tumors. The factors associated with poor response in the cohort of patients are younger age group, lower dose of radiation and post-operative radiotherapy compared to preoperative radiotherapy. The majority of the recurrent tumors were small indicating that biology of the disease is more important.

Keywords: Desmoid, Tumor, Treatment, Outcome

1. Introduction

Desmoid tumors (DT) are a rare locally aggressive disease with tendency for local recurrence [1] and the peak incidence age of 30-40 years [2].

DT prognostic factors are still conflicting like surgical margin [3, 4, 5-10], disease location [3, 5, 9, 11], age and gender [5, 8, 12, 13]. The various treatment options including surgery, radiotherapy and systemic agents are generally offered according to the disease presenting symptoms and progressiveness [14-20].

Complete surgical resection without causing significant morbidity can be challenging. The administration of adjuvant radiotherapy may improve local control but can cause side effects like fibrosis and wound healing problems [3, 4, 21, 22], rarely there is concerns about development of radiation induced second malignancies.

The aim of this work is to present our experience using multidisciplinary team to reach the best treatment outcome for this locally aggressive disease and report the long-term outcomes of treatment.

2. Methods

2.1. Study Design

The medical records of total of 72 consecutive patients diagnosed with DT over a period of 10 years between January 2009 and December 2018 were reviewed at Radiation Oncology section, King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, Saudi Arabia. All the patients had biopsy proven DT at our institution in addition to baseline and periodic follow up CT and/or MRI scans.

Radiotherapy was delivered as definitive, preoperative or postoperative treatment. Radiation doses were 50 - 66Gy in 2 Gy per fraction as preoperative, postoperative and definitive radiotherapy. Radiation energy was 4-6MeV delivered by either 3D-Conformal Radiation Therapy, Tomotherapy or Volumetric Modulated Arc Therapy techniques. Surgery was either wide local excision or intralesional debulking.

2.2. Statistical Analysis

Continuous data were checked for normality by using Shapiro Walk test. Kruskal Wallis H test was used to compare more than two groups of non-normally distributed

data. Percent of categorical variables were compared using Pearson's Chi-square test or Fisher's exact test when was appropriate. Stratification of Recurrence Free Survival was done according intention to treat (ITT). These time-to-event distributions were estimated using the method of Kaplan-Meier plot, and compared using two-sided exact log-rank test. All tests were two sided. All statistics were performed using SPSS 22.0 for windows (IBM Inc., Chicago, IL, USA) and Med Calc 13 for windows (Med Calc Software bvba, Ostend, Belgium).

3. Results

3.1. Patient Characteristics

Two patients opted to undergo observation only and 1 patient opted to receive systemic treatment with Sorafenib who were excluded from the study. Therefore, total of 69 patients were evaluated (Table 1).

The median age of patient was 27 years (range 15-66) and approximately two-thirds were females. The majority were younger patients aged less than 30 years (n=43, 62%).

Table 1. Basic characteristics and outcome of 69 patients with desmoid tumor.

Parameters	All patients (N=69)		Parameters	All patients (N=69)	
	No.	%		No.	%
Sex			Radiotherapy (RT)		
Male	21	30.4%	No	15	21.7%
Female	48	69.6%	Yes	54	78.3%
Age (years)			Surgery (S)		
Median (Range)	27 (15 – 66)		No	24	34.8%
≤30 years	43	62.3%	Yes	45	65.2%
>30 years	26	37.7%	Surgical margin	(N=45)	
Site of tumor			Negative	15	33.3%
Upper limb	15	21.7%	Positive	30	66.7%
Trunk	21	30.4%	RT dose	(N=54)	
Pelvis	15	21.7%	50Gy-25fraction	39	72.2%
Lower limb	18	26.1%	60Gy-30fraction	12	22.2%
Size of tumor (cm)			66Gy-33fraction	3	5.6%
Median (Range)	7 (3 – 25)		RT timing	(N=30)	
≤5 cm	20	29%	Preoperative	12	40%
>5 cm	49	71%	Postoperative	18	60%
Sequence			Response to ttt	(N=54)	
Surgery alone	15	21.7%	Complete Response	24	44.4%
RT alone	24	34.8%	Partial Response	18	33.3%
RT then Surgery	12	17.4%	Stable Disease	12	22.2%
Surgery then RT	18	26.1%	Recurrence	(N=45)	
			Negative	39	86.7%
			Positive	6	13.3%

3.1.1. Tumor Characteristics

The median size was 7 cm (range, 3-25cm) and nearly two third of the patients had tumors larger than 5 cm. The most common site was trunk (n=21, 30%), followed by lower limbs (n=18, 26%), pelvis (n=15, 22%), and upper limbs (n=15, 22%).

3.1.2. Treatment Characteristics

Twenty four patients were treated with definitive radiotherapy, 15 patients by surgical resection alone and 30 patients by combination of both surgery and radiotherapy (12 cases had preoperative and 18 cases had postoperative irradiation).

The surgical margin was positive in 30 patients out of total of

45 cases who had surgery (67%). Radiation was given to total of 54 cases with doses of 50Gy in 25 fractions delivered in 39 cases (72%) and 60- 66Gy in 15 cases (28%) (Table 2).

3.2. Response to Treatment

The median follow up was 5.5 years (range 1- 10yrs). The local control in patients who had radiotherapy (n=54 pts) as part of their treatment was 89%. The patients who had surgery (n=45 pts) as a part of the treatment had local control of 87% (Table 2).

3.3. Surgery Alone Group

The patients who had surgery (n=15) alone had no recurrence.

3.4. Radiotherapy Alone Group

The local control in patients who had definite radiotherapy (n=24) was 100% with partial response in 18 pts (75%) and stable disease in 6 pts (25%). All the patients who had definite radiotherapy had size greater than 5cm.

3.5. Combined Surgery and Radiotherapy Group

All the patients who had combined surgery and

radiotherapy (either pre or post-operative) had positive margins. The local control in patients with positive surgical margin (n=30 pts) and radiotherapy was 80% (n=6 patients developed recurrence). All the recurrences happened in the lower radiotherapy dose of 50Gy and those who had post-operative radiotherapy. There was no recurrence in the higher radiotherapy dose of 60Gy (p= 0.05) and those who had pre-operative radiotherapy (p=0.05). The patients group treated with surgery plus radiotherapy most of the recurrence was in patients with tumor size less than 5 cm (5 out of total of 6 recurrent patients). There was no recurrence in the patients with trunk site and all the recurrences happened in the extremities group. All the recurrences were in the less than 30 years group (Table 2).

3.6. Survival and Long Term Side Effects

The 3yrs, 5yrs and 7yrs recurrence free survival in patients who had both surgery and radiotherapy was 96.4%, 81.4% and 77.4% respectively. There was no grade 3 or 4 acute or late toxicity in all the groups of patients. There was no incidence of second malignancy in this cohort of patients at median follow up of 5.5 years (Figure 1).

Table 2. Comparison between the studied groups regarding basic characteristics and outcome. RFS recurrence free survival, ‡ Chi-square test; • Kruskal Wallis H test; † Log-rank test; p-value<0.05 is significant.

Parameters	Surgery (N=15)		Radiotherapy (N=24)		Surgery + RT (N=30)		p-value
	No.	%	No.	%	No.	%	
Sex							
Male	3	20%	12	50%	6	20%	0.036‡
Female	12	80%	12	50%	24	80%	
Age (years)							
Median (Range)	33 (19 – 42)		31 (15 – 66)		25 (16 – 42)		0.091•
≤30 years	7	46.7%	12	50%	24	80%	0.029‡
>30 years	6	53.3%	12	50%	6	20%	
Site of tumours							
Upper limb	0	0%	6	25%	9	30%	<0.001‡
Trunk	9	60%	0	0%	12	40%	
Pelvis	3	20%	9	37.5%	3	10%	
Lower limb	3	20%	9	37.5%	6	20%	
Tumour's Size (cm)							
Median (Range)	6 (4 – 10)		9 (6 – 25)		6 (3 – 11)		<0.001‡
≤5 cm	6	40%	0	0%	14	46.7%	
>5 cm	9	60%	24	100%	16	53.3%	
Response to ttt							
CR			0	0%	24	80%	<0.001‡
PR			18	75%	0	0%	
SD			6	25%	0	0%	
PD			0	0%	6	20%	
Recurrence							
Absent	15	100%			24	80%	0.157‡
Present	0	0%			6	20%	
RFS							
3-year RFS	100%				96.4%		0.191†
5-year RFS	100%				81.4%		
7-year RFS	100%				77.4%		




Figure 1. Kaplan Meier plot shows comparison between the studied groups regarding Recurrence Free Survival.

4. Discussion

Desmoid tumors are benign tumor of connective tissue but with high chances of local recurrence. Surgery is the main treatment modality of therapy if it can be done with acceptable morbidity. Radiotherapy is given in locally advanced inoperable tumors as definitive therapy or in combination with surgery in high risk tumors. The radiation dose used is 50-66Gy depending on the tolerance dose to the surrounding organs at risk. The clinical course can be variable and rarely may undergo spontaneous regression. Therefore, close observation to monitor the rate of growth is a reasonable option if patient is minimally symptomatic or even when the surgical margins are positive when resection is possible without significant morbidity.

In our cohort regarding to gender and age, females have aggressive disease similar to studies reported by [5, 8, 12 & 13] while age 30 years or less has poor prognosis as in series by [5, 8, 12] while aggressive in age more than 30 years in series by Rock et al [11] and less than 32 years by Sorensen et al [13].

In our study regarding to site, the extremities have a worse disease while the trunk has a more favorable outcome similar to Ballo et al [3], Broekhoven et al [8], Huang [9] and Rock et al [11] while non-significant in Merchant et al [5].

Our cohort showed recurrence free survival (RFS) of 96.4%, 81.4% and 77.4% at 3, 5 and 7 years of the group treated by surgery plus radiotherapy while Merchant et al [5] noticed the 2-year and 5-year local RFS rates of 80% and 75%, respectively, Zeng et al [10] had the estimated 5- and 10-year RFS of 74.2% and 70.7% respectively while Sorensen [13] showed the 5 year local RFS rate of 73%.

Local control in our cohort received irradiation as a part of treatment was 89% and 87% if surgery was a part of treatment, while Goy et al [4] noted the 6-year actuarial local control 78% (+/-14%) in cases managed by surgery and irradiation.

In our cohort, patients (n=30) with perioperative irradiation had positive margin with local control of 80% and

local recurrence in 20% (n=6), while Ballo et al [3] reported the 10-year actuarial relapse rate of 25%.

Our study showed that patients who had surgery alone with negative surgical margin did not have local recurrence with median 5.5 years follow up similar to results by Goy et al [4], Zeng et al [10] and Rock et al [11], contrary to Merchant et al [5], Broekhoven et al [8], Huang et al [9] and Shido et al [12].

Our cohort showed that the rate of disease recurrence is significant in lesion less than 5cm, extremities site, radiation dose 50Gy, age 30 years or less & patients received postoperative not preoperative irradiation. Contrary to Merchant et al [5] as all prognostic factors were insignificant for predicting local recurrence even positive margin, while Broekhoven et al [8] noted the risk of recurrence increased for extremity lesions, however insignificant of age, resection margins or adjuvant radiotherapy. Huang et al [9] noted that tumor site, size, and resection margin had significant impacts on event-free survival. Zeng et al [10] reported worse RFS in tumor size larger than 5 cm, extra-abdominal tumor sites and resection margin status. Rock et al [11] reported recurrence was evident in females, in patients more than thirty years old, in lower extremity locations and most importantly after treatment by intralesional or marginal excision. Shido et al [12] found that tumor size, surgical margin and previous surgical history were not associated with local recurrence, however younger age <30 years and females had local recurrence risk, suggesting the tumor effect biological behavior.

5. Conclusions

Radiotherapy plays an important role in local control of DT. The factors associated with poor response in the cohort of patients are younger age group, lower dose of radiation and post-operative radiotherapy compared to preoperative radiotherapy. The majority of the recurrent tumors were small indicating that biology of the disease is more important.

Authors' Contributions

MW Hegazy collected the data, wrote the manuscript while M Rizwanullah analyzed the data and shared in writing and reviewing the manuscript. All authors have read and approved the manuscript. I certify that; I am authorized by my co-author to enter into these arrangements.

Conflict of Interest

All authors declare that there is no conflict of interest.

References

- [1] Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Cesne AL et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. *Eur J Cancer* 2016; 58: 90e6.

- [2] Kasper B, Stroebe P, Hohenberger P. Desmoid tumors – clinical features and treatment options for advanced disease. *The Oncologist* 2011; 16: 682-93.
- [3] M. T. Ballo, G. K. Zagars, A. Pollack, P. W. Pisters, R. A. Pollack, Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy, *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 17 (1999) 158e167.
- [4] B. W. Goy, S. P. Lee, F. Eilber, F. Dorey, J. Eckardt, Y. S. Fu, G. J. Juillard, M. T. Selch, The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors, *Int. J. Radiat. Oncol. Biol. Phys.* 39 (1997) 659e665.
- [5] N. B. Merchant, J. J. Lewis, J. M. Woodruff, D. H. Leung, M. F. Brennan, Extremity and trunk desmoid tumors: a multifactorial analysis of outcome, *Cancer* 86 (1999) 2045e2052.
- [6] A. Gronchi, P. G. Casali, L. Mariani, S. Lo Vullo, M. Colecchia, L. Lozza, R. Bertulli, M. Fiore, P. Olmi, M. Santinami, J. Rosai, Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution, *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 21 (2003) 1390e1397.
- [7] K. Huang, H. Fu, Y.-Q. Shi, Y. Zhou, C.-Y. Du, Prognostic factors for extraabdominal and abdominal wall desmoids: a 20-year experience at a single institution, *J. Surg. Oncol.* 100 (2009) 563e569, <http://dx.doi.org/10.1002/jso.21384>.
- [8] D. L. M. van Broekhoven, C. Verhoef, S. G. Elias, A. J. Witkamp, J. M. H. H. van Gorp, B. a. N. van Geel, H. K. Wijrdeman, T. van Dalen, Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis, *Br. J. Surg.* 100 (2013) 1214e1219, <http://dx.doi.org/10.1002/bjs.9194>.
- [9] K. Huang, C. M. Wang, J. G. Chen, C. Y. Du, Y. Zhou, Y. Q. Shi, H. Fu, Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution, *Am. J. Surg.* 207 (2014) 847e854, <http://dx.doi.org/10.1016/j.amjsurg.2013.08.007>.
- [10] W.-G. Zeng, Z.-X. Zhou, J.-W. Liang, H.-R. Hou, Z. Wang, H.-T. Zhou, X.-M. Zhang, J.-J. Hu, Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution, *Tumour Biol. J. Int. Soc. Oncodevel. Biol. Med.* 35 (2014) 7513e7521, <http://dx.doi.org/10.1007/s13277-014-2002-1>.
- [11] M. G. Rock, D. J. Pritchard, H. M. Reiman, E. H. Soule, R. C. Brewster, Extraabdominal desmoid tumors, *J. Bone Jt. Surg. Am.* 66 (1984) 1369e1374.
- [12] Y. Shido, Y. Nishida, H. Nakashima, H. Katagiri, H. Sugiura, Y. Yamada, N. Ishiguro, Surgical treatment for local control of extremity and trunk desmoid tumors, *Arch. Orthop. Trauma Surg.* 129 (2009) 929e933, <http://dx.doi.org/10.1007/s00402-008-0750-3>.
- [13] A. Sørensen, J. Keller, O. S. Nielsen, O. M. Jensen, Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years, *Acta Orthop. Scand.* 73 (2002) 213e219, <http://dx.doi.org/10.1080/000164702753671830>.
- [14] A. Hansmann, C. Adolph, T. Vogel, A. Unger, G. Moeslein, High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors, *Cancer* 100 (2004) 612e620, <http://dx.doi.org/10.1002/cncr.11937>.
- [15] J. Janinis, M. Patriki, L. Vini, G. Aravantinos, J. S. Whelan, The pharmacological treatment of aggressive fibromatosis: a systematic review, *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO* 14 (2003) 181e190.
- [16] N. Penel, A. Le Cesne, B. N. Bui, D. Perol, E. G. Brain, I. Ray-Coquard, C. Guillemet, C. Chevreau, D. Cupissol, S. Chabaud, M. Jimenez, F. Duffaud, S. Piperno-Neumann, L. Mignot, J.-Y. Blay, Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up, *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO* 22 (2011) 452e457, <http://dx.doi.org/10.1093/annonc/mdq341>.
- [17] B. Kasper, P. Ströbel, P. Hohenberger, Desmoid tumors: clinical features and treatment options for advanced disease, *Oncology* 16 (2011) 682e693, <http://dx.doi.org/10.1634/theoncologist.2010-0281>.
- [18] S. Bonvalot, H. Eldweny, V. Haddad, F. Rimareix, G. Misenard, O. Oberlin, D. Vanel, P. Terrier, J. Y. Blay, A. Le Cesne, C. Le Pechoux, Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients, *Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol.* 34 (2008) 462e468, <http://dx.doi.org/10.1016/j.ejso.2007.06.006>.
- [19] N. Eastley, R. Aujla, R. Silk, C. J. Richards, T. A. McCulloch, C. P. Esler, R.U. Ashford, Extra-abdominal desmoid fibromatosis: a sarcoma unit review of practice, long term recurrence rates and survival, *Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol.* 40 (2014) 1125e1130, <http://dx.doi.org/10.1016/j.ejso.2014.02.226>.
- [20] E. Stoeckle, J. M. Coindre, M. Longy, M. B. N. Binh, G. Kantor, M. Kind, C. T. de Lara, A. Avril, F. Bonichon, B. N. Bui, A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases, *Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol.* 35 (2009) 129e134, <http://dx.doi.org/10.1016/j.ejso.2008.06.1495>.
- [21] O. Micke, M. H. Seegenschmiedt, German cooperative group on radiotherapy for benign diseases, radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study, *Int. J. Radiat. Oncol. Biol. Phys.* 61 (2005) 882e891, <http://dx.doi.org/10.1016/j.ijrobp.2004.07.705>.
- [22] J. J. Nuytens, P. F. Rust, C. R. Thomas, A. T. Turrisi, Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles, *Cancer* 88 (2000) 1517e1523.